Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study

Despite high tumor mutationburden, immune checkpoint blockade has limited efficacy in SCLC. We hypothesized that poly (ADP-ribose) polymerase inhibition could render SCLC more susceptible to immune checkpoint blockade. A single-arm, phase II trial (NCT02484404) enrolled patients with relapsed SCLC w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2019-08, Vol.14 (8), p.1447-1457
Hauptverfasser:	Thomas, Anish, Vilimas, Rasa, Trindade, Christopher, Erwin-Cohen, Rebecca, Roper, Nitin, Xi, Liqiang, Krishnasamy, Venkatesh, Levy, Elliot, Mammen, Andy, Nichols, Samantha, Chen, Yuanbin, Velcheti, Vamsidhar, Yin, Faye, Szabo, Eva, Pommier, Yves, Steinberg, Seth M., Trepel, Jane B., Raffeld, Mark, Young, Howard A., Khan, Javed, Hewitt, Stephen, Lee, Jung-Min
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use DNA repair Female Humans immune checkpoint blockade Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Middle Aged PARP inhibitors Phthalazines - pharmacology Phthalazines - therapeutic use Piperazines - pharmacology Piperazines - therapeutic use Recurrence Small cell lung cancer Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - pathology tumor immune phenotype
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!